Coloplast's stock rose 2.39% to DKK 433.0 following publication of the company's fiscal Q3 2025/26 interim results, which revealed organic revenue growth of 6% — above the analyst consensus of 5.65% and in line with reported growth in Danish kroner. That performance also comfortably exceeded the 4.44% median forecast on a reported basis.
Management highlighted the strength in the Chronic Care segment and identified substantial untapped potential in the U.S. market as central to Coloplast's long-term value creation priorities. Chief Executive Gavin Wood emphasized those points in commentary accompanying the results.
The revenue outperformance was broad across product divisions. Continence Care led with 8% organic growth, powered by double-digit expansion in the U.S. where Luja was cited as the primary growth driver. Interventional Urology advanced 7%, supported by continued momentum in U.S. men's health. Ostomy Care rose 5%, with notable double-digit U.S. growth outside China. Voice and Respiratory Care increased by 6%, and Wound and Tissue Repair grew 3%.
Despite the top-line beat, not all metrics met expectations. EBIT excluding special items was DKK 1.93 billion, slightly below the DKK 1.95 billion consensus. The EBIT margin came in at 26%, underperforming the 26.82% expected and declining from 28% a year earlier. Those profit metrics help explain why the stock reaction was measured rather than strongly positive.
Biologics represented the clearest area of weakness in the quarter. The division recorded a 6% sales decline and reported a negative 5% EBIT margin before purchase-price amortisation, a result the company attributed to a reimbursement change. In addition, currency effects reduced the group EBIT margin by around 110 basis points over the period, while the acquisition of Kerecis contributed an additional headwind of roughly 60 basis points.
Management left full-year guidance unchanged, maintaining a target of 5-6% organic revenue growth and around 5% EBIT growth in constant currencies. That decision, together with the revenue beat and the CEO's focus on Chronic Care and U.S. opportunity, provided supportive context that outweighed the modest profit shortfall and division-specific headwinds in the eyes of investors.
In summary, Coloplast delivered a clear top-line beat across multiple divisions and reiterated guidance, but margin pressure from Biologics, currency movements and acquisition-related effects limited the upside in the stock. The overall market reaction amounted to a contained positive move rather than a pronounced rally.
Quarter highlights
- Organic revenue growth: 6% (beat vs 5.65% consensus)
- Stock move: +2.39% to DKK 433.0
- EBIT (ex. special items): DKK 1.93 billion (consensus DKK 1.95 billion)
- EBIT margin: 26% (vs 26.82% expected; 28% a year earlier)